The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
[HTML][HTML] Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …
first documented pandemic due to a coronavirus that continues to be a major health …
Molnupiravir: A versatile prodrug against SARS-CoV-2 variants
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Abstract Background and Aims Vaccines are the first line of defense against coronavirus
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
Deuterated drugs and biomarkers in the COVID-19 pandemic
RD Jansen-van Vuuren, L Jedlovčnik, J Košmrlj… - ACS …, 2022 - ACS Publications
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan …
Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US
H Goswami, A Alsumali, Y Jiang, M Schindler… - …, 2022 - Springer
Background and aims Coronavirus disease 2019 (COVID-19) imposes a substantial and
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …
Synthetic approaches to the new drugs approved during 2021
EL McInturff, SP France, CA Leverett… - Journal of Medicinal …, 2023 - ACS Publications
Each year, new drugs are introduced to the market, representing structures that have affinity
for biological targets implicated in human diseases and conditions. These new chemical …
for biological targets implicated in human diseases and conditions. These new chemical …
Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19
Aims The aim of this study was to evaluate the safety profile of molnupiravir in COVID‐19
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …
Characteristics of the SARS-CoV-2 Omicron (B. 1.1. 529) variant and emerging impact on global public health
The discovery of the SARS-CoV-2 Omicron (B. 1.1. 529) variant has sparked alarm globally
because of its rapid rate of infection and trespassing acquired immunity due to vaccination …
because of its rapid rate of infection and trespassing acquired immunity due to vaccination …
[HTML][HTML] Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea
OBJECTIVES Many countries have authorized the emergency use of oral antiviral agents for
patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We …
patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We …